Tadalafil Tablet
Product Images NDC 82009-077

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 82009-077). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quallent Pharmaceuticals Health Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

20mg (Tadalafil 20mg)

Label for Tadalafil Tablets, USP 20 mg oral tablets by Quallent Pharmaceuticals Health LLC. The label includes dosage strength, a note that tablets should not be split, and storage instructions. It also states the product is manufactured by Ajanta Pharma Limited, India, and includes an NDC code 82009-079-05 as well as a barcode.*

FDA Label Image

5mg (Tadalafil 5mg)

Label for Tadalafil Tablets USP 5 mg, showing a 500 tablet package. The label includes manufacturer and distributor details: Ajanta Pharma Limited (India) and Quallent Pharmaceuticals Health LLC (Grand Cayman). It states the tablets are film-coated and contain FD&C Yellow No.5. Storage, dosage, and warning information is also present along with the NDC 82009-077-05 and a barcode.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The graph shows a greater reduction in scores with Tadalafil 5 mg across the duration, with data points at 0, 2, 4, 8, and 12 weeks and a significance indicator (p<0.01) at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs displaying blood pressure changes over time comparing tadalafil to placebo. The graphs show Standing Systolic BP, Standing Diastolic BP, Supine Systolic BP, and Supine Diastolic BP measured across various time points up to 96 hours. The y-axis represents the difference in mmHg, and the x-axis represents time in hours.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs depicting the effects on standing and supine systolic blood pressure (mmHg) over 24 hours after dosing. The top graph compares Tadalafil 20 mg with doxazosin 8 mg to placebo with doxazosin 8 mg for standing systolic blood pressure. The bottom graph shows the same comparison for supine systolic blood pressure over the same time.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph displaying the change in systolic blood pressure (mmHg) over time after administration of tadalafil or placebo, both combined with doxazosin. The x-axis represents time after administration (hours), while the y-axis shows systolic blood pressure changes, featuring different curves for 20 mg and 8 mg tadalafil compared to placebo at morning and evening dosing times.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (mcg/L) over time (hours) after administration. It compares single 20-mg and 5-mg tadalafil doses, plus once-daily 5-mg tadalafil after 5 consecutive days, showing concentration changes and variability with error bars over a 120-hour period.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration. The graph shows two lines: one for Tadalafil 5 mg and one for placebo, with Tadalafil demonstrating a greater decrease in IPSS score over time compared to placebo. The x-axis represents weeks of treatment, and the y-axis represents change from baseline in the score, with significance indicated at p<0.01.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment with Tadalafil 5 mg versus placebo. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline. Tadalafil 5 mg shows a greater decrease in IPSS score than placebo, with significant differences marked at selected points.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph depicting the least-squares mean change from baseline over weeks of therapy for two groups: Tadalafil/Finasteride and Placebo/Finasteride. The y-axis shows the change from baseline, and the x-axis represents weeks of therapy (0, 4, 12, 26). The graph includes markers and trend lines with annotated statistical significance indicators (p-values).*

FDA Label Image

Logo (Tadalafil Logo)

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil, the active ingredient in this product. The diagram shows the molecular framework including fused rings and functional groups characteristic of Tadalafil's compound structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.